AGL 37.85 Decreased By ▼ -0.09 (-0.24%)
AIRLINK 160.49 Increased By ▲ 5.27 (3.4%)
BOP 8.95 Decreased By ▼ -0.12 (-1.32%)
CNERGY 6.85 Increased By ▲ 0.13 (1.93%)
DCL 10.10 Increased By ▲ 0.57 (5.98%)
DFML 40.30 Decreased By ▼ -0.01 (-0.02%)
DGKC 92.30 Decreased By ▼ -0.65 (-0.7%)
FCCL 38.10 Decreased By ▼ -0.28 (-0.73%)
FFBL 78.45 Decreased By ▼ -0.13 (-0.17%)
FFL 13.50 Decreased By ▼ -0.10 (-0.74%)
HUBC 113.90 Increased By ▲ 3.71 (3.37%)
HUMNL 14.64 Decreased By ▼ -0.25 (-1.68%)
KEL 5.63 Decreased By ▼ -0.10 (-1.75%)
KOSM 8.25 Decreased By ▼ -0.22 (-2.6%)
MLCF 44.78 Decreased By ▼ -0.88 (-1.93%)
NBP 74.98 Decreased By ▼ -1.19 (-1.56%)
OGDC 192.00 Increased By ▲ 0.13 (0.07%)
PAEL 31.65 Increased By ▲ 1.17 (3.84%)
PIBTL 8.68 Increased By ▲ 0.52 (6.37%)
PPL 166.75 Increased By ▲ 0.19 (0.11%)
PRL 31.25 Increased By ▲ 1.81 (6.15%)
PTC 22.08 Increased By ▲ 2.01 (10.01%)
SEARL 98.30 Increased By ▲ 1.68 (1.74%)
TELE 8.51 Increased By ▲ 0.24 (2.9%)
TOMCL 34.80 Increased By ▲ 0.54 (1.58%)
TPLP 11.12 Increased By ▲ 0.90 (8.81%)
TREET 18.52 Increased By ▲ 0.86 (4.87%)
TRG 60.90 Decreased By ▼ -0.35 (-0.57%)
UNITY 32.00 Increased By ▲ 0.03 (0.09%)
WTL 1.53 Increased By ▲ 0.06 (4.08%)
BR100 11,249 Increased By 33.2 (0.3%)
BR30 33,968 Increased By 317.6 (0.94%)
KSE100 104,841 Increased By 281.9 (0.27%)
KSE30 32,438 Increased By 72.6 (0.22%)
Business & Finance

Novartis in talks on helping make COVID-19 vaccines, tests

  • Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry.
  • We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible.
Published January 28, 2021

ZURICH: Novartis is talking to other companies about helping to make vaccines and tests for COVID-19, the Swiss drugmaker said on Thursday without providing more details.

"Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry, and leverage our manufacturing capacity and capabilities to contribute to the pandemic effort," it said in response to a query.

"We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible."

Novartis last year agreed to license two of Molecular Partners' antiviral drugs that it hopes to use to treat COVID-19 patients.

Novartis's gene therapy unit AveXis also last year signed a manufacturing agreement to produce a novel genetic COVID-19 vaccine being developed by the US-based Mass General Brigham health care system.

Comments

Comments are closed.